Status:
COMPLETED
Dupilumab for Severe Asthma in a Real Life Setting
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Severe Asthma
Eligibility:
All Genders
18+ years
Brief Summary
Dupilumab is a monoclonal anti-IL-4/13Rα antibody developed for severe asthma (SA). In France, mepolizumab was commercialized in February 2018. Before this date, many SA patients had reached a therape...
Detailed Description
Introduction: Asthma is a worldwide burden affecting more than 300 millions patients. Although the vast majority of asthma patients suffer from mild to moderate diseases whose symptoms can be assesse...
Eligibility Criteria
Inclusion
- French patient with Severe Asthma
- Administration of dupilumab under the TUA between September 2017 and January 2018, with at least one injection
- Realization of at least one follow-up visit in the first 12 months of treatment
Exclusion
- None
Key Trial Info
Start Date :
August 10 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 2 2019
Estimated Enrollment :
86 Patients enrolled
Trial Details
Trial ID
NCT04022447
Start Date
August 10 2018
End Date
April 2 2019
Last Update
August 6 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bichat-Claude Bernard University Hospital
Paris, France, 75018